{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:38:50Z","timestamp":1793047130672,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Despite some studies suggesting a possible association between human leukocyte antigen, <jats:italic>HLA-B*5801<\/jats:italic> and allopurinol induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), the evidence of association and its magnitude remain inconclusive. This study aims to systematically review and meta-analyze the association between <jats:italic>HLA-B*5801<\/jats:italic> allele and allopurinol-induced SJS\/TEN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A comprehensive search was performed in databases including MEDLINE, Pre-MEDLINE, Cochrane Library, EMBASE, International Pharmaceutical Abstracts (IPA), CINAHL, PsychInfo, the WHO International, Clinical Trial Registry, and ClinicalTrial.gov from their inceptions to June 2011. Only studies investigating association between <jats:italic>HLA-B*5801<\/jats:italic> with allopurinol-induced SJS\/TEN were included. All studies were extracted by two independent authors. The primary analysis was the carrier frequency of <jats:italic>HLA-B*5801<\/jats:italic> comparison between allopurinol-induced SJS\/TEN cases and each comparative group. The pooled odds ratios were calculated using a random effect model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 4 studies with 55 SJS\/TEN cases and 678 matched-controls (allopurinol-tolerant control) was identified, while 5 studies with 69 SJS\/TEN cases and 3378 population-controls (general population) were found. SJS\/TEN cases were found to be significantly associated with <jats:italic>HLA-B*5801<\/jats:italic> allele in both groups of studies with matched-control (OR 96.60, 95%CI 24.49-381.00, p &lt; 0.001) and population-control (OR 79.28, 95%CI 41.51-151.35, p &lt; 0.001). Subgroup analysis for Asian and Non-Asian population yielded similar findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We found a strong and significant association between <jats:italic>HLA-B*5801<\/jats:italic> and allopurinol-induced SJS\/TEN. Therefore, <jats:italic>HLA-B*5801<\/jats:italic> allele screening may be considered in patients who will be treated with allopurinol.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2350-12-118","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T23:14:31Z","timestamp":1315610071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":192,"title":["Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"12","author":[{"given":"Ratchadaporn","family":"Somkrua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E","family":"Eickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surasak","family":"Saokaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manupat","family":"Lohitnavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"issue":"1","key":"851_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","volume":"126","author":"H Chan","year":"1990","unstructured":"Chan H, Stern R, Arndt K, Langlois J, Jick S, Jick H, Walker A: The incidence of erythema multiforme, sevens-johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990, 126 (1): 43-47. 10.1001\/archderm.126.1.43.","journal-title":"Arch Dermatol"},{"issue":"19","key":"851_CR2","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","volume":"331","author":"JC Roujeau","year":"1994","unstructured":"Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994, 331 (19): 1272-1285. 10.1056\/NEJM199411103311906.","journal-title":"N Engl J Med"},{"issue":"7","key":"851_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","volume":"49","author":"B Rzany","year":"1996","unstructured":"Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E: Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol. 1996, 49 (7): 769-773. 10.1016\/0895-4356(96)00035-2.","journal-title":"J Clin Epidemiol"},{"key":"851_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1027\/0838-1925.14.4.143","volume":"14","author":"M Mockenhaupt","year":"2002","unstructured":"Mockenhaupt M, Norgauer J: Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int. 2002, 14: 143-150. 10.1027\/0838-1925.14.4.143.","journal-title":"Allergy Clin Immunol Int"},{"issue":"6","key":"851_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/CCM.0b013e31821201ed","volume":"39","author":"R Gerull","year":"2011","unstructured":"Gerull R, Nelle M, Schaible T: Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review. Crit Care Med. 2011, 39 (6): 1521-1532. 10.1097\/CCM.0b013e31821201ed.","journal-title":"Crit Care Med"},{"issue":"2","key":"851_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","volume":"209","author":"JC Roujeau","year":"2005","unstructured":"Roujeau JC: Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005, 209 (2): 123-129. 10.1016\/j.tox.2004.12.022.","journal-title":"Toxicology"},{"issue":"1","key":"851_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","volume":"128","author":"M Mockenhaupt","year":"2008","unstructured":"Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008, 128 (1): 35-44. 10.1038\/sj.jid.5701033.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"851_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/rheumatology\/38.12.1301","volume":"38","author":"R Melsom","year":"1999","unstructured":"Melsom R: Familial hypersensitivity to allopurinol with subsequent desensitization. Rheumatology (Oxford). 1999, 38 (12): 1301-10.1093\/rheumatology\/38.12.1301.","journal-title":"Rheumatology (Oxford)"},{"key":"851_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","volume":"7","author":"WH Chung","year":"2007","unstructured":"Chung WH, Hung SI, Chen YT: Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2007, 7: 317-323. 10.1097\/ACI.0b013e3282370c5f.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"11","key":"851_CR10","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, et al: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005, 102 (11): 4134-4139. 10.1073\/pnas.0409500102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"851_CR11","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","volume":"9","author":"N Kaniwa","year":"2008","unstructured":"Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, et al: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008, 9 (11): 1617-1622. 10.2217\/14622416.9.11.1617.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"851_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, et al: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008, 18 (2): 99-107. 10.1097\/FPC.0b013e3282f3ef9c.","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"851_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","volume":"19","author":"W Tassaneeyakul","year":"2009","unstructured":"Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, et al: Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009, 19 (9): 704-709. 10.1097\/FPC.0b013e328330a3b8.","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"851_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","volume":"21","author":"HR Kang","year":"2011","unstructured":"Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, et al: Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011, 21 (5): 303-307. 10.1097\/FPC.0b013e32834282b8.","journal-title":"Pharmacogenet Genomics"},{"key":"851_CR15","first-page":"1","volume":"0","author":"JW Jung","year":"2011","unstructured":"Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, et al: HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011, 0: 1-6.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"851_CR16","doi-asserted-by":"publisher","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","volume":"102","author":"JC Roujeau","year":"1994","unstructured":"Roujeau JC: The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994, 102 (6): 28S-30S. 10.1111\/1523-1747.ep12388434.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"851_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"S Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin S, Rzany B, Stern R: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erytherma multiforme. Arch Dermatol. 1993, 129 (1): 92-96. 10.1001\/archderm.129.1.92.","journal-title":"Arch Dermatol"},{"issue":"1","key":"851_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2332\/allergolint.55.9","volume":"55","author":"LE French","year":"2006","unstructured":"French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006, 55 (1): 9-16. 10.2332\/allergolint.55.9.","journal-title":"Allergol Int"},{"key":"851_CR19","unstructured":"Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (Accessed June 1, 2011), [http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp]"},{"key":"851_CR20","first-page":"139","volume-title":"Clin Transpl","author":"H Tanaka","year":"1996","unstructured":"Tanaka H, Akaza T, Juji T: Report of the Japanese Central Bone Marrow Data Center. Clin Transpl. 1996, 139-144."},{"issue":"3","key":"851_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188. 10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"issue":"11","key":"851_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"J Higgins","year":"2002","unstructured":"Higgins J, Thompson S: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21 (11): 1539-1558. 10.1002\/sim.1186.","journal-title":"Stat Med"},{"issue":"2","key":"851_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jnci\/81.2.107","volume":"81","author":"C Begg","year":"1989","unstructured":"Begg C, Berlin J: Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989, 81 (2): 107-115. 10.1093\/jnci\/81.2.107.","journal-title":"J Natl Cancer Inst"},{"issue":"7124","key":"851_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","volume":"316","author":"M Egger","year":"1998","unstructured":"Egger M, Smith G: Bias in location and selection of studies. BMJ. 1998, 316 (7124): 61-66.","journal-title":"BMJ"},{"issue":"1","key":"851_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/1471-2458-11-221","volume":"11","author":"T Hanioka","year":"2011","unstructured":"Hanioka T, Ojima M, Tanaka K, Matsuo K, Sato F, Tanaka H: Causal assessment of smoking and tooth loss: A systematic review of observational studies. BMC Public Health. 2011, 11 (1): 221-10.1186\/1471-2458-11-221.","journal-title":"BMC Public Health"},{"issue":"1","key":"851_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2288-7-32","volume":"7","author":"Y Loke","year":"2007","unstructured":"Loke Y, Price D, Herxheimer A, the Cochrane Adverse Effects Methods G: Systematic reviews of adverse effects: framework for a structured approach. BMC Medical Research Methodology. 2007, 7 (1): 32-10.1186\/1471-2288-7-32.","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"851_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2458-9-51","volume":"9","author":"L Smith","year":"2009","unstructured":"Smith L, Foxcroft D: The effect of alcohol advertising, marketing and portrayal on drinking behaviour in young people: systematic review of prospective cohort studies. BMC Public Health. 2009, 9 (1): 51-10.1186\/1471-2458-9-51.","journal-title":"BMC Public Health"},{"issue":"1","key":"851_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2393-10-63","volume":"10","author":"H Wahabi","year":"2010","unstructured":"Wahabi H, Alzeidan R, Bawazeer G, Alansari L, Esmaeil S: Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy and Childbirth. 2010, 10 (1): 63-10.1186\/1471-2393-10-63.","journal-title":"BMC Pregnancy and Childbirth"},{"issue":"9","key":"851_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.tig.2004.06.014","volume":"20","author":"MR Munafo","year":"2004","unstructured":"Munafo MR, Flint J: Meta-analysis of genetic association studies. Trends Genet. 2004, 20 (9): 439-444. 10.1016\/j.tig.2004.06.014.","journal-title":"Trends Genet"},{"issue":"10","key":"851_CR30","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1056\/NEJM200009073431006","volume":"343","author":"J Klein","year":"2000","unstructured":"Klein J, Sato A: The HLA system, first of two parts. N Engl J Med. 2000, 343 (10): 702-709. 10.1056\/NEJM200009073431006.","journal-title":"N Engl J Med"},{"key":"851_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","volume":"58","author":"S Halevy","year":"2008","unstructured":"Halevy S, Mockenhaupt M, Fagot JP, Bavinck JNB, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC: Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008, 58: 25-32. 10.1016\/j.jaad.2007.08.036.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"851_CR32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","volume":"27","author":"F Arellano","year":"1993","unstructured":"Arellano F, Sacristan JA: Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993, 27 (3): 337-343.","journal-title":"Ann Pharmacother"},{"key":"851_CR33","first-page":"656","volume":"7","author":"A Markel","year":"2005","unstructured":"Markel A: Allopurinol-induced DRESS syndrome. Isr Med Assoc J. 2005, 7: 656-660.","journal-title":"Isr Med Assoc J"},{"key":"851_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nrd1605","volume":"4","author":"PJ Bugelski","year":"2005","unstructured":"Bugelski PJ: Genetic aspects of immune-mediated adverse drug effects. Nat Rev Drug Discov. 2005, 4: 59-69. 10.1038\/nrd1605.","journal-title":"Nat Rev Drug Discov"},{"key":"851_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0966-3274(02)00059-X","volume":"10","author":"S Stevanovic","year":"2002","unstructured":"Stevanovic S: Structural basis of immunogenicity. Transpl Immunol. 2002, 10: 133-136. 10.1016\/S0966-3274(02)00059-X.","journal-title":"Transpl Immunol"},{"issue":"2","key":"851_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/toxsci\/kfg078","volume":"73","author":"YC Ou","year":"2003","unstructured":"Ou YC, Conolly RB, Thomas RS, Gustafson DL, Long ME, Dobrev ID, Chubb LS, Xu Y, Lapidot SA, Andersen ME, et al: Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay. Toxicol Sci. 2003, 73 (2): 301-314. 10.1093\/toxsci\/kfg078.","journal-title":"Toxicol Sci"},{"issue":"2","key":"851_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1006\/taap.1997.8248","volume":"146","author":"RB Conolly","year":"1997","unstructured":"Conolly RB, Andersen ME: Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and of CYP 1A1\/1A2 as a dosimeter. Toxicol Appl Pharmacol. 1997, 146 (2): 281-293. 10.1006\/taap.1997.8248.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"851_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00204-007-0238-x","volume":"82","author":"Y Lu","year":"2008","unstructured":"Lu Y, Lohitnavy M, Reddy M, Lohitnavy O, Eickman E, Ashley A, Gerjevic L, Xu Y, Conolly RB, Yang RS: Quantitative analysis of liver GST-P foci promoted by a chemical mixture of hexachlorobenzene and PCB 126: implication of size-dependent cellular growth kinetics. Arch Toxicol. 2008, 82 (2): 103-116. 10.1007\/s00204-007-0238-x.","journal-title":"Arch Toxicol"},{"issue":"5","key":"851_CR39","first-page":"1879","volume":"61","author":"YC Ou","year":"2001","unstructured":"Ou YC, Conolly RB, Thomas RS, Xu Y, Andersen ME, Chubb LS, Pitot HC, Yang RS: A clonal growth model: time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay. Cancer Res. 2001, 61 (5): 1879-1889.","journal-title":"Cancer Res"},{"issue":"5","key":"851_CR40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995, 3 (5): 541-547. 10.1016\/1074-7613(95)90125-6.","journal-title":"Immunity"},{"issue":"5238","key":"851_CR41","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995, 270 (5238): 985-988. 10.1126\/science.270.5238.985.","journal-title":"Science"},{"issue":"6","key":"851_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2217\/14622416.7.6.813","volume":"7","author":"A Alfirevic","year":"2006","unstructured":"Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006, 7 (6): 813-818. 10.2217\/14622416.7.6.813.","journal-title":"Pharmacogenomics"},{"issue":"4","key":"851_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","volume":"16","author":"SI Hung","year":"2006","unstructured":"Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, et al: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006, 16 (4): 297-306. 10.1097\/01.fpc.0000199500.46842.4a.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"851_CR44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","volume":"51","author":"H Ikeda","year":"2010","unstructured":"Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, Aihara M, Kashiwagi M, Muramatsu M: HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010, 51 (2): 297-300. 10.1111\/j.1528-1167.2009.02269.x.","journal-title":"Epilepsia"},{"issue":"5","key":"851_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1034\/j.1399-0039.2003.00062.x","volume":"61","author":"D Middleton","year":"2003","unstructured":"Middleton D, Menchaca L, Rood H, Komerofsky R: New allele frequency database: http:\/\/www.allelefrequencies.net. Tissue Antigens. 2003, 61 (5): 403-407. 10.1034\/j.1399-0039.2003.00062.x.","journal-title":"Tissue Antigens"},{"issue":"12","key":"851_CR46","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","volume":"51","author":"N Kaniwa","year":"2010","unstructured":"Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, et al: HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010, 51 (12): 2461-2465. 10.1111\/j.1528-1167.2010.02766.x.","journal-title":"Epilepsia"},{"issue":"3 Suppl","key":"851_CR47","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jaci.2010.11.046","volume":"127","author":"EJ Phillips","year":"2011","unstructured":"Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA: Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011, 127 (3 Suppl): S60-66.","journal-title":"J Allergy Clin Immunol"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-12-118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2350-12-118\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-12-118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-12-118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T16:25:38Z","timestamp":1630513538000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/1471-2350-12-118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1186\/1471-2350-12-118","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]},"assertion":[{"value":"24 February 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"118"}}